The FDA has returned to releasing pharma rejection letters (CRLs), posting 14 new complete response letters online after a brief pause. The agency framed the shift around a renewed emphasis on transparency, according to coverage of the updated posting activity. The development matters for clinical-stage companies because CRLs can directly alter development timelines, trial designs, and manufacturing remediation plans. It also signals that the FDA’s approach to public disclosure of CRL details is evolving again following scrutiny and legal risk concerns. Biotech planning teams are likely to watch whether additional CRL batches continue and whether the FDA’s messaging becomes more consistent across applications.